皮肤冠状动脉干预后左心室射出小部分的变化:与预后的相关性和关联
Gjin Ndrepepa1, Salvatore Cassese1, Robert A Byrne2,3
1Department of Cardiology, Deutsches Herzzentrum München Technische Universität München Munich Germany.
Journal of the American Heart Association
|October 18, 2024
概括
穿皮冠状动脉干预 (PCI) 可以改善左心室喷射率 (LVEF),显著降低冠状动脉疾病和减少LVEF的患者的长期死亡率. 在PCI后的LVEF改善与更好的生存率有关.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 心血管研究成果研究结果
背景情况:
- 穿皮冠状动脉干预 (PCI) 后左心室喷射率 (LVEF) 变化对冠状动脉疾病 (CAD) 患者长期死亡率的影响需要进一步调查.
- 了解LVEF改善和PCI后生存率之间的关系对于优化患者管理至关重要.
研究的目的:
- 为了评估PCI对患有CAD的患者LVEF的影响.
- 确定PCI后LVEF变化 (ΔLVEF) 与5年死亡率之间的关联.
主要方法:
- 对8181名接受PCI的CAD患者进行了观察性研究.
- 在基线和PCI后6-8个月的对联LVEF测量.
- 基于ΔLVEF类别 (减少,轻微改善,大大改善) 和基线LVEF的5年死亡率分析.
主要成果:
- PCI导致LVEF显著改善,特别是在基线LVEF较低的患者中.
- ΔLVEF 的较大改善与所有原因和心脏病死亡的5年死亡率显著降低有关.
- 改善LVEF的死亡益处在基线LVEF<40%的患者中最为明显.
结论:
- 在PCI后LVEF的改善与冠状动脉疾病患者的长期死亡率降低有关.
- 这种生存益处在干预前减少了LVEF的患者中尤为明显.
相关概念视频
Acute Coronary Syndrome III: Diagnostic studies
3
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
3
Cardiomyopathy V: Interprofessional Care
1
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
1
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...


